AbbVie's upadacitinib successful in third late-stage dermatitis study (NYSE:ABBV

published 28.07.2020 11:20

Image of article 'AbbVie's upadacitinib successful in third late-stage dermatitis study (NYSE:ABBV'

AbbVie (NYSE:ABBV) announces another successful Phase 3 clinical trial, AD Up, evaluating Rinvoq (upadacitinib) plus topical corticosteroids (TCS) in adults and adolescents with moderate-to-severe atopic dermatitis.

Specifically, 77% of patients receiving 30 mg of upadacitinib plus TCS achieved EASI 75 (75% improvement in EASI score) compared to 26% in the placebo arm.

59% of patients in the cohort achieved clear or almost clear skin compared to 11% in the control arm.

64% experienced at least a four-grade improvement in itchy skin compared to 15% in the control arm.

Two previous Phase 3s, MEASURE Up 1 & MEASURE Up 2, were also successful.

by Douglas W. House from seekingalpha.com

Free awesomeness straight to your inbox!

Sign up now for this free newsletter to receive hand picked content, covering topics like Lifestyle, Business & Technology.

Free Newsletter Sign up now!

..or jump directly to the latest posts!